

# Axel Grothey

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6865314/axel-grothey-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

246  
papers

20,392  
citations

59  
h-index

141  
g-index

273  
ext. papers

24,446  
ext. citations

7.3  
avg, IF

6.58  
L-index

#	Paper	IF	Citations
246	Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors.. <i>JCO Precision Oncology</i> , <b>2022</b> , 6, e2100181	3.6	2
245	Landscape of , Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in -Mutated Cancers.. <i>JCO Precision Oncology</i> , <b>2022</b> , 6, e2100245	3.6	2
244	Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. <i>Npj Precision Oncology</i> , <b>2021</b> , 5, 95	9.8	1
243	Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. <i>Oncologist</i> , <b>2021</b> , 26, 610-618	5.7	
242	Use of Molecular Assays and Circulating Tumor DNA in Early-Stage Colorectal Cancer: A Roundtable Discussion of the Gastrointestinal Cancer Therapy Expert Group. <i>Oncologist</i> , <b>2021</b> , 26, 651-659	5.7	3
241	Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> , 325, 1277-1286	27.4	12
240	Early-onset stage II/III colorectal adenocarcinoma in the IDEA database: Treatment adherence, toxicities, and outcomes from adjuvant fluoropyrimidine and oxaliplatin.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3517-3517	2.2	
239	Molecular correlates of clinical benefit in previously treated patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3513-3513	2.2	3
238	Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 779-789	21.7	53
237	Overall survival (OS) with encorafenib (enco) + cetuximab (cetux) in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3583-3583	2.2	0
236	Clinical and Functional Characterization of Atypical / Mutations in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 4587-4598	12.9	4
235	Precision Medicine for the Treatment of Colorectal Cancer: the Evolution and Status of Molecular Profiling and Biomarkers. <i>Current Colorectal Cancer Reports</i> , <b>2021</b> , 17, 55-68	1	1
234	Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types. <i>Cancer Management and Research</i> , <b>2021</b> , 13, 5523-5533	3.6	1
233	Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 1174-1183	12.9	7
232	Analysis of the Survival Impact of Postoperative Chemotherapy After Preoperative Chemotherapy and Resection for Gastric Cancer. <i>Annals of Surgical Oncology</i> , <b>2021</b> , 28, 1417-1427	3.1	4
231	Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer. <i>Therapeutic Advances in Gastroenterology</i> , <b>2021</b> , 14, 17562848211024460	4.7	3
230	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. <i>Therapeutic Advances in Medical Oncology</i> , <b>2021</b> , 13, 17588359211020547	5.4	2

229	Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 642-651	2.2	27
228	Evolution and Current Status of the Multidisciplinary Management of Locally Advanced Rectal Cancer. <i>JCO Oncology Practice</i> , <b>2021</b> , 17, 383-402	2.3	3
227	Microsatellite Stable Colorectal Liver Metastases-Understanding the Mechanisms of Immune Resistance. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2119025	10.4	0
226	BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer. <i>BMJ Open</i> , <b>2021</b> , 11, e04783 <sup>3</sup>		2
225	Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2021</b> , 6, 933-946	18.8	6
224	Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study.. <i>ESMO Open</i> , <b>2021</b> , 6, 100328	6	2
223	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet, The</i> , <b>2020</b> , 395, 1907-1918	18.8	0
222	-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype. <i>Cancers</i> , <b>2020</b> , 12,	6.6	7
221	Evolution of Cancer Care in Response to the COVID-19 Pandemic. <i>Oncologist</i> , <b>2020</b> , 25, e1426-e1427	5.7	5
220	Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance). <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920910913	5.4	6
219	A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. <i>Oncologist</i> , <b>2020</b> , 25, e936-e945	5.7	356
218	Molecular profile of BRCA-mutated biliary tract cancers. <i>ESMO Open</i> , <b>2020</b> , 5, e000682	6	34
217	Evolving role of regorafenib for the treatment of advanced cancers. <i>Cancer Treatment Reviews</i> , <b>2020</b> , 86, 101993	14.4	24
216	EGFR antibodies in resectable metastatic colorectal liver metastasis: more harm than benefit?. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 324-326	21.7	6
215	A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4000-4000	2.2	37
214	Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4001-4001	2.2	22
213	Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4004-4004	2.2	23
212	Personalizing Treatment for Rectal Cancer: Total Neoadjuvant Therapy Is Leading the Way. <i>JAMA Network Open</i> , <b>2020</b> , 3, e2030508	10.4	0

211	Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer. <i>Oncologist</i> , <b>2020</b> , 25, 404-413	5.7	13
210	Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trials. <i>Contemporary Clinical Trials Communications</i> , <b>2020</b> , 17, 100492	1.8	3
209	Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. <i>Pancreatology</i> , <b>2020</b> , 20, 101-109	3.8	12
208	A new prognostic and predictive tool for shared decision making in stage III colon cancer. <i>European Journal of Cancer</i> , <b>2020</b> , 138, 182-188	7.5	7
207	Molecular characteristics of and mutations in pancreatic ductal adenocarcinoma. <i>ESMO Open</i> , <b>2020</b> , 5, e000942	6	11
206	Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 1620-1629	21.7	55
205	Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 2948-2956	7.5	32
204	Encorafenib, Binimetinib, and Cetuximab in V600E-Mutated Colorectal Cancer. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1632-1643	59.2	481
203	Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D levels and survival among patients with metastatic colorectal cancer. <i>Cancer Causes and Control</i> , <b>2019</b> , 30, 757-765	2.8	2
202	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , <b>2019</b> , 5, 1008-1019	13.4	288
201	Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1460-1469	2.2	114
200	Case series of dabrafenib-trametinib-induced pyrexia successfully treated with colchicine. <i>Supportive Care in Cancer</i> , <b>2019</b> , 27, 3869-3875	3.9	5
199	Impact of Tumor Location and Variables Associated With Overall Survival in Patients With Colorectal Cancer: A Mayo Clinic Colon and Rectal Cancer Registry Study. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 76	5.3	19
198	Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 1070-1082	21.7	101
197	Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. <i>Oncologist</i> , <b>2019</b> , 24, 185-192	5.7	52
196	Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metastatic Renal Cell and Colorectal Cancers. <i>Journal of the American Society of Echocardiography</i> , <b>2019</b> , 32, 267-276	5.8	11
195	Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, 52-57	3.8	21
194	Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. <i>Molecular Cancer Research</i> , <b>2018</b> , 16, 805-812	6.6	114

193	Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic Experience. <i>Oncologist</i> , <b>2018</b> , 23, 1083-1091	5.7	24
192	MODUL-a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2018</b> , 144, 1197-1204	4.9	11
191	NCCN Guidelines Insights: Colon Cancer, Version 2.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2018</b> , 16, 359-369	7.3	433
190	A Curative-Intent Trimodality Approach for Isolated Abdominal Nodal Metastases in Metastatic Colorectal Cancer: Update of a Single-Institutional Experience. <i>Oncologist</i> , <b>2018</b> , 23, 679-685	5.7	8
189	Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set. <i>ESMO Open</i> , <b>2018</b> , 3, e000347	6	13
188	Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 1177-1188	59.2	429
187	Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). <i>Journal of Geriatric Oncology</i> , <b>2018</b> , 9, 24-31	3.6	8
186	Impact of Metastasectomy in the Multimodality Approach for V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience. <i>Oncologist</i> , <b>2018</b> , 23, 128-134	5.7	25
185	5-fluorouracil and cardiotoxicity: a review. <i>Therapeutic Advances in Medical Oncology</i> , <b>2018</b> , 10, 17588359-18780140	3.1	147
184	Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2018</b> , 16, 852-871	7.3	63
183	Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2018</b> , 16, 874-901	7.3	429
182	Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: The IDEA collaboration.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3599-3599	2.2	4
181	Evaluation of lesion-based response at 12 weeks (LBR12) of treatment (Rx) in metastatic colorectal cancer (mCRC): Findings from 9,092 patients (pts) in the ARCAD database.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 612-612	2.2	1
180	Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance). <i>International Journal of Statistics in Medical Research</i> , <b>2018</b> , 7, 137-146	3	
179	Leptomeningeal Carcinomatosis in Colorectal Cancer: The Mayo Clinic Experience. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, e183-e187	3.8	6
178	A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 316-325	12.9	10
177	Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 1451-1455	8.7	14
176	Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. <i>European Journal of Cancer</i> , <b>2018</b> , 103, 205-213	7.5	9

175	Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2018</b> , 82, 961-969	3.5	16
174	Chemotherapy-Induced Neutropenia as a Prognostic and Predictive Marker of Outcomes in Solid-Tumor Patients. <i>Drugs</i> , <b>2018</b> , 78, 737-745	12.1	17
173	Optimizing Adjuvant Therapy for Localized Colon Cancer and Treatment Selection in Advanced Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2018</b> , 16, 611-615	7.3	9
172	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. <i>European Journal of Cancer</i> , <b>2018</b> , 100, 35-45	7.5	20
171	Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor. <i>Drugs</i> , <b>2017</b> , 77, 1091-1103	12.1	78
170	Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2017</b> , 15, 370-398	7.3	485
169	Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU). <i>American Journal of Hematology</i> , <b>2017</b> , 92, 1004-1010	7.1	6
168	Evidence in Favor of Standard Surgical Treatment for Rectal Cancer. <i>JAMA Oncology</i> , <b>2017</b> , 3, 885-886	13.4	3
167	Continued disappointments with targeted agents in first-line therapy of advanced gastric cancers. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 1427-1428	21.7	2
166	Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment. <i>Cancer Management and Research</i> , <b>2017</b> , 9, 149-158	3.6	10
165	BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2624-2630	2.2	176
164	Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1929-1937	2.2	28
163	Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , <b>2017</b> , 16, 124-128	3.8	28
162	Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies. <i>Therapeutic Advances in Medical Oncology</i> , <b>2017</b> , 9, 106-126	5.4	22
161	Heterogeneity in early lesion changes on treatment as a marker of poor prognosis in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line systemic chemotherapy ± biologic: Findings from 9,092 pts in the ARCAD database.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3535-3535	2.2	4
160	Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). <i>Supportive Care in Cancer</i> , <b>2016</b> , 24, 5059-5068	3.9	50
159	Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance). <i>Oncologist</i> , <b>2016</b> , 21, 1509-1521	5.7	24
158	Adverse event development in clinical oncology trials - AuthorsPreply. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, e264-e265	21.7	1

157	Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 1709-1719	21.7	258
156	Chemotherapy Maintenance. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2016</b> , 22, 199-204	2.2	24
155	Regorafenib in the treatment of colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 137-454		10
154	Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1182-9	2.2	22
153	MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. <i>Supportive Care in Cancer</i> , <b>2016</b> , 24, 1071-8	3.9	36
152	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , <b>2016</b> , 1, e000097	6	59
151	Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies. <i>Investigational New Drugs</i> , <b>2016</b> , 34, 96-103	4.3	1
150	Therapy: Colorectal cancer: how to teach an old drug new tricks. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2016</b> , 13, 384-5	24.2	1
149	Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 663-70	21.7	69
148	Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study. <i>BMC Cancer</i> , <b>2016</b> , 16, 4674.8		43
147	Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. <i>Oncologist</i> , <b>2016</b> , 21, 1306-1314	5.7	27
146	Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations. <i>Investigational New Drugs</i> , <b>2015</b> , 33, 740-50	4.3	73
145	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 937-48	21.7	240
144	Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , <b>2015</b> , 41, 653-9	14.4	41
143	When less is more: maintenance therapy in colorectal cancer. <i>Lancet, The</i> , <b>2015</b> , 385, 1808-10	40	11
142	Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 499-508	21.7	568
141	Distinctive Tumor Biology of MSI-High Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , <b>2015</b> , 11, 281-287	1	1
140	Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance). <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3416-22	2.2	167

139	New Adjuvant Trial Designs in Colon Cancer. <i>Current Colorectal Cancer Reports</i> , <b>2015</b> , 11, 326-334	1	2
138	Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 22-8	2.2	69
137	Rectal Cancer, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2015</b> , 13, 719-28; quiz 728	7.3	154
136	Optimizing systemic therapy selection in metastatic colorectal cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2015</b> , 13, 682-5	7.3	2
135	Calcium and Magnesium Use for Oxaliplatin-Induced Neuropathy: A Case Study to Assess How Quickly Evidence Translates Into Practice. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2015</b> , 13, 1097-101	7.3	10
134	Molecular profiling in the treatment of colorectal cancer: focus on regorafenib. <i>OncoTargets and Therapy</i> , <b>2015</b> , 8, 2949-57	4.4	6
133	Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer. <i>Case Reports in Oncological Medicine</i> , <b>2015</b> , 2015, 420159	0.9	4
132	Gastrointestinal cancer: Rationale for metronomic chemotherapy in phase III trials. <i>Nature Reviews Clinical Oncology</i> , <b>2015</b> , 12, 313-4	19.4	22
131	The role of regorafenib in metastatic colorectal cancer. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 596-7	21.7	4
130	Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	16
129	The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	52
128	Colorectal cancer in 2014: progress in defining first-line and maintenance therapies. <i>Nature Reviews Clinical Oncology</i> , <b>2015</b> , 12, 73-4	19.4	35
127	Metastatic extramammary Paget's disease responding to weekly paclitaxel. <i>BMJ Case Reports</i> , <b>2015</b> , 2015,	0.9	3
126	Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients <b>2015</b> , 2,		5
125	Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations. <i>Clinical Advances in Hematology and Oncology</i> , <b>2015</b> , 13, 514-7	0.6	14
124	Introduction to special issue on biomarker-based clinical trial designs in oncology. <i>Chinese Clinical Oncology</i> , <b>2015</b> , 4, 28	2.3	
123	Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. <i>Clinical Colorectal Cancer</i> , <b>2014</b> , 13, 100-9	3.8	36
122	Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2014</b> , 23, 726-34	2.6	36



121	Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106,	9.7	109
120	Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 997-1005	2.2	156
119	Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouse. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 841-50	2.2	35
118	The search for treatments to reduce chemotherapy-induced peripheral neuropathy. <i>Journal of Clinical Investigation</i> , <b>2014</b> , 124, 72-4	15.9	13
117	Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care. <i>Oncologist</i> , <b>2014</b> , 19, 669-80	5.7	53
116	ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106,	9.7	48
115	Drug rechallenge and treatment beyond progression--implications for drug resistance. <i>Nature Reviews Clinical Oncology</i> , <b>2013</b> , 10, 571-87	19.4	174
114	A home-based exercise program to improve function, fatigue, and sleep quality in patients with Stage IV lung and colorectal cancer: a randomized controlled trial. <i>Journal of Pain and Symptom Management</i> , <b>2013</b> , 45, 811-21	4.8	165
113	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , <b>2013</b> , 381, 303-12	4 <sup>0</sup>	1783
112	The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. <i>Current Colorectal Cancer Reports</i> , <b>2013</b> , 9, 261-269	1	82
111	Regorafenib for metastatic colorectal cancer - AuthorsPreply. <i>Lancet, The</i> , <b>2013</b> , 381, 1538-9	40	6
110	VEGF inhibition beyond tumour progression. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, 2-3	21.7	8
109	Systemic cytotoxic and biologic therapies for colorectal cancer liver metastases: expert consensus statement. <i>Hpb</i> , <b>2013</b> , 15, 116-8	3.8	3
108	Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3656-63	2.2	56
107	Adolescent and young adult colorectal cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2013</b> , 11, 1219-25	7.3	39
106	Exploring racial differences in outcome and treatment for metastatic colorectal cancer: results from a large prospective observational cohort study (BRiTE). <i>Cancer</i> , <b>2012</b> , 118, 1083-90	6.4	29
105	Optimal Treatment Strategies for Localized and Advanced Microsatellite Instability-High Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , <b>2012</b> , 8, 36-41	1	
104	Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. <i>Oncologist</i> , <b>2012</b> , 17, 1486-95	5.7	82

103	Treatment options for advanced pancreatic cancer: a review. <i>Expert Review of Anticancer Therapy</i> , <b>2012</b> , 12, 1327-36	3.5	32
102	S-1 in colorectal cancer: a new standard of care?. <i>Lancet Oncology</i> , <b>2012</b> , 13, 1068-70	21.7	
101	Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2012</b> , 307, 1383-93	27.4	330
100	Hepatic artery embolization for neuroendocrine tumors: postprocedural management and complications. <i>Oncologist</i> , <b>2012</b> , 17, 725-31	5.7	28
99	Reply to M. Mandal et al. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1895-1895	2.2	
98	Reply to S.A. Kesikli et al. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2288-2289	2.2	1
97	Antiangiogenesis therapy in the treatment of metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , <b>2012</b> , 4, 301-19	5.4	25
96	Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 546-54	12.9	111
95	Establishing a standard of care for small bowel adenocarcinomas: challenges and lessons learned. <i>Oncologist</i> , <b>2012</b> , 17, 1133-4	5.7	
94	A factor found in the IgG fraction of serum of patients with paraneoplastic bilateral diffuse uveal melanocytic proliferation causes proliferation of cultured human melanocytes. <i>Retina</i> , <b>2012</b> , 32, 1959-66	3.6	56
93	Regorafenib in metastatic colorectal cancer. <i>Clinical Advances in Hematology and Oncology</i> , <b>2012</b> , 10, 324-5	0.6	6
92	Recent developments in therapy for gastrointestinal cancers. <i>Community Oncology</i> , <b>2011</b> , 8, 4-8		
91	Reduced Chemotherapy Duration: A Good Idea?. <i>Current Colorectal Cancer Reports</i> , <b>2011</b> , 7, 241-245	1	
90	Curable metastatic colorectal cancer. <i>Current Oncology Reports</i> , <b>2011</b> , 13, 168-76	6.3	34
89	Prognostic web-based models for stage II and III colon cancer: A population and clinical trials-based validation of numeracy and adjuvant! online. <i>Cancer</i> , <b>2011</b> , 117, 4155-65	6.4	21
88	Integrating biomarkers in clinical trials. <i>Expert Review of Molecular Diagnostics</i> , <b>2011</b> , 11, 171-82	3.8	104
87	Should oncologists routinely discuss fertility preservation with cancer patients of childbearing age?. <i>Mayo Clinic Proceedings</i> , <b>2011</b> , 86, 6-7	6.4	4
86	Reply to A. Chan et al. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, e490-e491	2.2	

85	Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741. <i>Oncologist</i> , <b>2011</b> , 16, 859-67	5.7	13
84	KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice. <i>Oncologist</i> , <b>2011</b> , 16, 1061-8	5.7	14
83	Does stage II colorectal cancer need to be redefined?. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 3053-5	12.9	6
82	Reply to S.B. Park et al. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, e555-e556	2.2	
81	Waiting in line for cancer treatments?. <i>Gastrointestinal Cancer Research: GCR</i> , <b>2011</b> , 4, 147-9		
80	Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1936-41	2.2	72
79	Reply to D.J. Stewart. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e652-e653	2.2	3
78	Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 460-5	2.2	49
77	Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3219-26	2.2	1063
76	Biomarkers and surrogate end points--the challenge of statistical validation. <i>Nature Reviews Clinical Oncology</i> , <b>2010</b> , 7, 309-17	19.4	240
75	Reintroduction of oxaliplatin: a viable approach to the long-term management of metastatic colorectal cancer. <i>Oncology</i> , <b>2010</b> , 79, 389-99	3.6	23
74	Randomized phase II trials: inevitable or inadvisable?. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2641-7	2.2	61
73	Antiangiogenesis agents in colorectal cancer. <i>Current Opinion in Oncology</i> , <b>2010</b> , 22, 374-80	4.2	24
72	The role of chemotherapy in managing patients with resectable liver metastases. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2010</b> , 16, 125-31	2.2	6
71	Adjuvant therapy for colon cancer: learning from the past to inform the future. <i>Annals of Surgical Oncology</i> , <b>2010</b> , 17, 947-9	3.1	5
70	Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3227-33	2.2	182
69	Strategies for Managing Chemotherapy-Induced Sensory Neuropathy. <i>Current Colorectal Cancer Reports</i> , <b>2010</b> , 6, 126-132	1	
68	Adjuvant chemotherapy for resected stage II and III colon cancer: comparison of two widely used prognostic calculators. <i>Seminars in Oncology</i> , <b>2010</b> , 37, 39-46	5.5	20

67	Risk assessment in stage II colon cancer: to treat or not to treat?. <i>Oncology</i> , <b>2010</b> , 24, 1-2	1.8	1
66	Medical treatment of advanced colorectal cancer in 2009. <i>Therapeutic Advances in Medical Oncology</i> , <b>2009</b> , 1, 55-68	5.4	7
65	Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1948-55	2.2	125
64	Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3677-83	2.2	955
63	Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 872-7	2.2	400
62	Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 7492-7501	12.9	42
61	Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. <i>Oncologist</i> , <b>2009</b> , 14, 862-70	5.7	256
60	Reply to F. Montagnani et al. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, e134-e135	2.2	
59	Adding cetuximab to a standard chemotherapy regimen containing bevacizumab in first-line therapy for colorectal cancer decreases efficacy: Results from the CAIRO2 trial. <i>Current Colorectal Cancer Reports</i> , <b>2009</b> , 5, 65-66	1	
58	A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer. <i>Nature Clinical Practice Oncology</i> , <b>2009</b> , 6, 10-1		5
57	Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. <i>Nature Reviews Clinical Oncology</i> , <b>2009</b> , 6, 507-18	19.4	297
56	North Central Cancer Treatment Group--achievements and perspectives. <i>Seminars in Oncology</i> , <b>2008</b> , 35, 530-44	5.5	4
55	Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer. <i>Clinical Colorectal Cancer</i> , <b>2008</b> , 7, 60-4	3.8	26
54	Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5326-34	2.2	561
53	Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 183-9	2.2	153
52	Phase I trial of a pathotropic retroviral vector expressing a cytotoxic cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer. <i>Molecular Therapy</i> , <b>2008</b> , 16, 979-84	11.7	37
51	Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective. <i>Statistical Methods in Medical Research</i> , <b>2008</b> , 17, 529-35	2.3	6
50	Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2008</b> , 14, 170-7	2.2	57

49	Targeting colorectal cancer with human anti-EGFR monoclonal antibodies: focus on panitumumab. <i>Biologics: Targets and Therapy</i> , <b>2008</b> , 2, 223-8	4.4	29
48	Should bevacizumab be continued beyond progression in colorectal cancer?. <i>Current Colorectal Cancer Reports</i> , <b>2008</b> , 4, 139-143	1	
47	Improving the Odds for a Patient With Potentially Curable Stage IV Colorectal Cancer: A Question of Chemosensitivity. <i>Gastrointestinal Cancer Research: GCR</i> , <b>2008</b> , 2, 258-60		
46	Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. <i>Cancer</i> , <b>2007</b> , 110, 670-7	6.4	27
45	The continuum of care: a paradigm for the management of metastatic colorectal cancer. <i>Oncologist</i> , <b>2007</b> , 12, 38-50	5.7	190
44	Biological therapy and other novel therapies in early-stage disease: are they appropriate?. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 6909s-12s	12.9	6
43	New approaches to assessing and treating early-stage colon and rectal cancer: summary statement from 2007 Santa Monica Conference. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 6853s-6s	12.9	12
42	Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 4217-23	2.2	235
41	Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancer. <i>Seminars in Oncology</i> , <b>2006</b> , 33, S41-9	5.5	12
40	Does bevacizumab improve survival in patients with metastatic colorectal cancer treated with chemotherapy?. <i>Nature Clinical Practice Oncology</i> , <b>2006</b> , 3, 22-3		1
39	First- and second-line therapy of metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2006</b> , 6, 921-30	3.5	15
38	Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 2903-9	2.2	942
37	Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. <i>Clinical Colorectal Cancer</i> , <b>2006</b> , 6, 29-31	3.8	123
36	Do all patients with metastatic colorectal cancer need chemotherapy until disease progression?. <i>Clinical Colorectal Cancer</i> , <b>2006</b> , 6, 196-201	3.8	6
35	Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial. <i>Clinical Colorectal Cancer</i> , <b>2006</b> , 6, 261-4	3.8	19
34	Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. <i>Annals of Surgical Oncology</i> , <b>2006</b> , 13, 1261-8	3.1	264
33	Antiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomiting. <i>Oncology Research and Treatment</i> , <b>2005</b> , 28, 88-92	2.8	5
32	FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 3311-3	2.2	20

31	Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 8664-70	2.2	509
30	Clinical trial designs for prospective validation of biomarkers. <i>Molecular Diagnosis and Therapy</i> , <b>2005</b> , 5, 317-25		39
29	N0147: a randomized phase III trial of oxaliplatin plus 5-fluorouracil/leucovorin with or without cetuximab after curative resection of stage III colon cancer. <i>Clinical Colorectal Cancer</i> , <b>2005</b> , 5, 211-3	3.8	24
28	Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy. <i>European Journal of Haematology</i> , <b>2005</b> , 74, 263-6	3.8	45
27	Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysis. <i>Supportive Care in Cancer</i> , <b>2005</b> , 13, 26-31	3.9	16
26	Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 4853-5	2.2	135
25	A review of oxaliplatin and its clinical use in colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2004</b> , 5, 2159-70	4	79
24	Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 1209-14	2.2	888
23	Developments in combination chemotherapy for colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2004</b> , 4, 627-37	3.5	4
22	Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers. <i>Clinical Colorectal Cancer</i> , <b>2004</b> , 4, 46-50	3.8	23
21	Oxaliplatin plus oral fluoropyrimidines in colorectal cancer. <i>Clinical Colorectal Cancer</i> , <b>2004</b> , 4 Suppl 1, S37-42	3.8	13
20	Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer. <i>Cancer Research</i> , <b>2003</b> , 63, 513-21	10.1	89
19	A low dose of ionizing radiation increases luminal release of intestinal peptidases in rats. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2001</b> , 127, 96-100	4.9	10
18	Cyclooxygenase-2: a novel target for cancer chemotherapy?. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2001</b> , 127, 411-7	4.9	339
17	New chemotherapy approaches in colorectal cancer. <i>Current Opinion in Oncology</i> , <b>2001</b> , 13, 275-86	4.2	42
16	Cisplatin resistance and oncogenes--a review. <i>Anti-Cancer Drugs</i> , <b>2000</b> , 11, 225-36	2.4	89
15	C-erbB-2/ HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines. <i>Oncogene</i> , <b>2000</b> , 19, 4864-75	9.2	90
14	Low E-cadherin and beta-catenin expression correlates with increased spontaneous and artificial lung metastases of murine carcinomas. <i>Clinical and Experimental Metastasis</i> , <b>1999</b> , 17, 171-6	4.7	12

13	Preferential repair of the N-ras gene in K 562 cells after exposure to cisplatin. <i>Anti-Cancer Drugs</i> , <b>1999</b> , 10, 545-9	2.4	3
12	Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma. <i>Anti-Cancer Drugs</i> , <b>1998</b> , 9, 405-9	2.4	10
11	Minimally Invasive Surgery [Where are We? is there a Role for TEM?73-88		1
10	Does Lifestyle Cause Colorectal Cancer?1-13		1
9	The Role of the Colorectal Nurse Specialist in the Management of Colorectal Cancer153-166		1
8	The Role of the Multidisciplinary Team in the Management of Colorectal Cancer167-177		
7	Follow-Up after Colorectal Cancer Resection: Is it Worth While?178-194		
6	Surgery for Metastatic Disease in Colorectal Cancer213-231		
5	Palliative Care of the Colorectal Cancer Patient232-250		
4	Future Directions in the Oncological Treatment of Colorectal Cancer251-270		
3	MRI-Directed Rectal Cancer Surgery46-59		
2	What is the Best Strategy for the Management of Hereditary Colorectal Cancer?89-111		
1	Adjuvant Radiotherapy and Chemoradiotherapy in the Treatment of Rectal Cancer112-132		